PPARs hold promise as a potential therapeutic target for treating AD, as PPAR agonists are commonly used in chronic neurodegenerative diseases and are widely expressed in the brain, especially in the hippocampus [108]. This evidence concerns the gene PPARA and Alzheimer disease.